This single-blind trial (n=15) will investigate the effects of intramuscularly administered 5-MeO-DMT on various aspects of human brain activity and well-being in healthy adults.
The study, conducted by Swinburne University of Technology in Australia and funded by Psychedelic Research in Science & Medicine (PRISM) Ltd, aims to enhance scientific comprehension of 5-MeO-DMT’s impact through psychological, physiological, and biological markers.
Participants, aged between 18 and 40 years, will undergo four dosing days spaced two weeks apart, receiving doses of 3 mg, 6 mg, and 9 mg of 5-MeO-DMT, alongside an inactive placebo. A psychiatrist or medical practitioner will administer the intervention.
The primary outcome will assess the acute and post-acute effects of 5-MeO-DMT on frequency oscillatory power bands via magnetoencephalography (MEG), while secondary outcomes include evaluations of neurobiological activity, emotional regulation, and other psychological factors using various scales and questionnaires.
Recruitment is anticipated to begin in September 2023 in Victoria, Australia. Principal Investigator Prof Susan Rossell can be contacted for further information.
Trial Details
This study aims to improve the scientific understanding of the effects of intramuscularly (IM) administered 5-MeO-DMT on human brain activity as well as other indexes of well-being as assessed through psychological, physiological, and biological markers. Finally, we aim to further our understanding of the tolerability and safety profile as well as dose-dependent effects of different doses of 5-MeO-DMT or placebo administered per intramuscular administration and to uncover its phenomenological characteristics.NCT Number ACTRN12623000884606
Sponsors & Collaborators
Swinburne University of TechnologySwinburne University of Technology, located in Melbourne, Australia, is known for its focus on innovation, industry engagement, and social inclusion.
PRISM